| Rosaura Orengo-aguayo, PHD | |
|
67 President St # St861, Charleston, SC 29425-5712 | |
| (843) 792-2947 | |
| Not Available |
| Full Name | Rosaura Orengo-aguayo |
|---|---|
| Gender | Female |
| Speciality | Psychologist - Clinical |
| Location | 67 President St # St861, Charleston, South Carolina |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1023527504 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 103TC0700X | Psychologist - Clinical | 1474 (South Carolina) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Rosaura Orengo-aguayo, PHD 1710 Winfield Way, Charleston, SC 29414-8127 Ph: (319) 471-5326 | Rosaura Orengo-aguayo, PHD 67 President St # St861, Charleston, SC 29425-5712 Ph: (843) 792-2947 |
News Archive
Purdue Pharma L.P. announced today that the U.S. Food and Drug Administration (FDA) approved Butrans™ (buprenorphine) Transdermal System CIII for the management of moderate to severe chronic pain in patients requiring a continuous, around-the-clock opioid analgesic for an extended period of time. Butrans Transdermal System is an analgesic product that delivers continuous release of medication for seven days.
According to SDI's 2010 Ranking Tables Study, office-based primary care physicians - general practitioners, family medicine physicians, and doctors of osteopathy - rank GlaxoSmithKline's sales force number one, a jump from third in 2009. Pfizer finished second and Merck placed third this year, down from first and second, respectively, in 2009.
NexMed, Inc., a specialty CRO with a pipeline of products based on the NexACT® technology, today announced that the U.S. Food & Drug Administration (FDA) has cleared the Company to proceed with the proposed Phase 2 trial of PrevOnco™, its proprietary cancer treatment for patients with advanced, unresectable hepatocellular carcinoma (HCC), or liver cancer. The FDA granted PrevOnco™ orphan drug status in August 2008, and in March 2010, NexMed filed its Investigational New Drug (IND) application for the product candidate.
The battle over health care is sparking claims on both sides, but many of the assertions being made twist the facts and others are outright false, says the editor of a Web site that tracks the claims.
Researchers at Yale School of Medicine have found that new disease pathways involving more than one cell type leads to Type 1 Gaucher disease, a rare genetic disorder in which fatty substances called glycosphingolipids accumulate in cells, resulting in liver/spleen enlargement, osteoporosis, bone pain, and increased risk of cancer and Parkinson's disease.
› Verified 8 days ago
Dr. Anna Birks, PSYD Psychologist Medicare: Not Enrolled in Medicare Practice Location: 109 Bee Street, Charleston, SC 29401 Phone: 843-789-7316 | |
Christine Reineke Bachmann, PSY.D. Psychologist Medicare: Accepting Medicare Assignments Practice Location: 1 Poston Rd, Suite 145, Charleston, SC 29407 Phone: 843-556-4157 Fax: 843-763-8747 | |
Dr. Janet Rose, PH.D. Psychologist Medicare: Not Enrolled in Medicare Practice Location: 215 E Bay St, Suite 501, Charleston, SC 29401 Phone: 843-708-4308 Fax: 843-723-8324 | |
Dr. Kathryn Reid, PH.D. Psychologist Medicare: Not Enrolled in Medicare Practice Location: 1016 Telfair Way, Charleston, SC 29412 Phone: 804-338-1820 | |
Mrs. Angela Geddes, ED.S. Psychologist Medicare: Not Enrolled in Medicare Practice Location: 505 Arlington Dr, Charleston, SC 29414 Phone: 843-606-0136 | |
Dr. Ashley Marie Fowler, PSYD. Psychologist Medicare: Not Enrolled in Medicare Practice Location: 1525 Sam Rittenberg Blvd Ste 103, Charleston, SC 29407 Phone: 509-680-0093 | |
David Brian Haver Jr., PSYD Psychologist Medicare: Accepting Medicare Assignments Practice Location: 171 Ashley Ave, Charleston, SC 29425 Phone: 843-792-1414 |